+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Genome Editing/Genome Engineering - Global Market Trajectory & Analytics

  • ID: 4805049
  • Report
  • April 2021
  • Region: Global
  • 148 pages
  • Global Industry Analysts, Inc
Global Genome Editing/Genome Engineering Market to Reach $10.3 Billion by 2027

Amid the COVID-19 crisis, the global market for Genome Editing/Genome Engineering estimated at US$4.1 Billion in the year 2020, is projected to reach a revised size of US$10.3 Billion by 2027, growing at a CAGR of 14% over the analysis period 2020-2027. CRISPR, one of the segments analyzed in the report, is projected to record a 14.8% CAGR and reach US$4.3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the TALEN segment is readjusted to a revised 14.2% CAGR for the next 7-year period.



The U.S. Market is Estimated at $1.2 Billion, While China is Forecast to Grow at 13.4% CAGR

The Genome Editing/Genome Engineering market in the U.S. is estimated at US$1.2 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2027 trailing a CAGR of 13.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.5% and 11.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 10.1% CAGR.

ZFN Segment to Record 12.6% CAGR

In the global ZFN segment, USA, Canada, Japan, China and Europe will drive the 12.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$840.5 Million in the year 2020 will reach a projected size of US$1.9 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.2 Billion by the year 2027.

Select Competitors (Total 44 Featured):
  • CRISPR Therapeutics AG
  • Editas Medicine, Inc.
  • GenScript Biotech Corporation
  • Horizon Discovery Group PLC
  • Integrated DNA Technologies (IDT), Inc.
  • Lonza Group AG
  • Merck & Co., Inc.
  • New England Biolabs, Inc.
  • OriGene Technologies, Inc.
  • Sangamo Therapeutics
  • Thermo Fisher Scientific, Inc.
  • Transposagen Biopharmaceuticals, Inc.
Note: Product cover images may vary from those shown
I. METHODOLOGY

II. EXECUTIVE SUMMARY
  • Influencer Market Insights
  • Impact of Covid-19 and a Looming Global Recession
  • Table 1: World Current & Future Analysis for Genome Editing/Genome Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 2: World 7-Year Perspective for Genome Editing/Genome Engineering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
  • Table 3: World Current & Future Analysis for CRISPR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 4: World 7-Year Perspective for CRISPR by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 5: World Current & Future Analysis for TALEN by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 6: World 7-Year Perspective for TALEN by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 7: World Current & Future Analysis for ZFN by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 8: World 7-Year Perspective for ZFN by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 9: World Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 10: World 7-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 11: World Current & Future Analysis for Cell Line Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 12: World 7-Year Perspective for Cell Line Engineering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 13: World Current & Future Analysis for Animal Genetic Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 14: World 7-Year Perspective for Animal Genetic Engineering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 15: World Current & Future Analysis for Plant Genetic Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 16: World 7-Year Perspective for Plant Genetic Engineering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 17: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 18: World 7-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
III. MARKET ANALYSIS
  • Table 19: USA Current & Future Analysis for Genome Editing/Genome Engineering by Technology - CRISPR, TALEN, ZFN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 20: USA 7-Year Perspective for Genome Editing/Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, TALEN, ZFN and Other Technologies for the Years 2020 & 2027
  • Table 21: USA Current & Future Analysis for Genome Editing/Genome Engineering by Application - Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 22: USA 7-Year Perspective for Genome Editing/Genome Engineering by Application - Percentage Breakdown of Value Sales for Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering and Other Applications for the Years 2020 & 2027
  • Table 23: Canada Current & Future Analysis for Genome Editing/Genome Engineering by Technology - CRISPR, TALEN, ZFN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 24: Canada 7-Year Perspective for Genome Editing/Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, TALEN, ZFN and Other Technologies for the Years 2020 & 2027
  • Table 25: Canada Current & Future Analysis for Genome Editing/Genome Engineering by Application - Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 26: Canada 7-Year Perspective for Genome Editing/Genome Engineering by Application - Percentage Breakdown of Value Sales for Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering and Other Applications for the Years 2020 & 2027
  • Table 27: Japan Current & Future Analysis for Genome Editing/Genome Engineering by Technology - CRISPR, TALEN, ZFN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 28: Japan 7-Year Perspective for Genome Editing/Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, TALEN, ZFN and Other Technologies for the Years 2020 & 2027
  • Table 29: Japan Current & Future Analysis for Genome Editing/Genome Engineering by Application - Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 30: Japan 7-Year Perspective for Genome Editing/Genome Engineering by Application - Percentage Breakdown of Value Sales for Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering and Other Applications for the Years 2020 & 2027
  • Table 31: China Current & Future Analysis for Genome Editing/Genome Engineering by Technology - CRISPR, TALEN, ZFN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 32: China 7-Year Perspective for Genome Editing/Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, TALEN, ZFN and Other Technologies for the Years 2020 & 2027
  • Table 33: China Current & Future Analysis for Genome Editing/Genome Engineering by Application - Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 34: China 7-Year Perspective for Genome Editing/Genome Engineering by Application - Percentage Breakdown of Value Sales for Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering and Other Applications for the Years 2020 & 2027
  • Table 35: Europe Current & Future Analysis for Genome Editing/Genome Engineering by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 36: Europe 7-Year Perspective for Genome Editing/Genome Engineering by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
  • Table 37: Europe Current & Future Analysis for Genome Editing/Genome Engineering by Technology - CRISPR, TALEN, ZFN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 38: Europe 7-Year Perspective for Genome Editing/Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, TALEN, ZFN and Other Technologies for the Years 2020 & 2027
  • Table 39: Europe Current & Future Analysis for Genome Editing/Genome Engineering by Application - Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 40: Europe 7-Year Perspective for Genome Editing/Genome Engineering by Application - Percentage Breakdown of Value Sales for Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering and Other Applications for the Years 2020 & 2027
  • Table 41: France Current & Future Analysis for Genome Editing/Genome Engineering by Technology - CRISPR, TALEN, ZFN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 42: France 7-Year Perspective for Genome Editing/Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, TALEN, ZFN and Other Technologies for the Years 2020 & 2027
  • Table 43: France Current & Future Analysis for Genome Editing/Genome Engineering by Application - Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 44: France 7-Year Perspective for Genome Editing/Genome Engineering by Application - Percentage Breakdown of Value Sales for Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering and Other Applications for the Years 2020 & 2027
  • Table 45: Germany Current & Future Analysis for Genome Editing/Genome Engineering by Technology - CRISPR, TALEN, ZFN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 46: Germany 7-Year Perspective for Genome Editing/Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, TALEN, ZFN and Other Technologies for the Years 2020 & 2027
  • Table 47: Germany Current & Future Analysis for Genome Editing/Genome Engineering by Application - Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 48: Germany 7-Year Perspective for Genome Editing/Genome Engineering by Application - Percentage Breakdown of Value Sales for Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering and Other Applications for the Years 2020 & 2027
  • Table 49: Italy Current & Future Analysis for Genome Editing/Genome Engineering by Technology - CRISPR, TALEN, ZFN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 50: Italy 7-Year Perspective for Genome Editing/Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, TALEN, ZFN and Other Technologies for the Years 2020 & 2027
  • Table 51: Italy Current & Future Analysis for Genome Editing/Genome Engineering by Application - Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 52: Italy 7-Year Perspective for Genome Editing/Genome Engineering by Application - Percentage Breakdown of Value Sales for Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering and Other Applications for the Years 2020 & 2027
  • Table 53: UK Current & Future Analysis for Genome Editing/Genome Engineering by Technology - CRISPR, TALEN, ZFN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 54: UK 7-Year Perspective for Genome Editing/Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, TALEN, ZFN and Other Technologies for the Years 2020 & 2027
  • Table 55: UK Current & Future Analysis for Genome Editing/Genome Engineering by Application - Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 56: UK 7-Year Perspective for Genome Editing/Genome Engineering by Application - Percentage Breakdown of Value Sales for Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering and Other Applications for the Years 2020 & 2027
  • Table 57: Rest of Europe Current & Future Analysis for Genome Editing/Genome Engineering by Technology - CRISPR, TALEN, ZFN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 58: Rest of Europe 7-Year Perspective for Genome Editing/Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, TALEN, ZFN and Other Technologies for the Years 2020 & 2027
  • Table 59: Rest of Europe Current & Future Analysis for Genome Editing/Genome Engineering by Application - Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 60: Rest of Europe 7-Year Perspective for Genome Editing/Genome Engineering by Application - Percentage Breakdown of Value Sales for Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering and Other Applications for the Years 2020 & 2027
  • Table 61: Asia-Pacific Current & Future Analysis for Genome Editing/Genome Engineering by Technology - CRISPR, TALEN, ZFN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 62: Asia-Pacific 7-Year Perspective for Genome Editing/Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, TALEN, ZFN and Other Technologies for the Years 2020 & 2027
  • Table 63: Asia-Pacific Current & Future Analysis for Genome Editing/Genome Engineering by Application - Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 64: Asia-Pacific 7-Year Perspective for Genome Editing/Genome Engineering by Application - Percentage Breakdown of Value Sales for Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering and Other Applications for the Years 2020 & 2027
  • Table 65: Rest of World Current & Future Analysis for Genome Editing/Genome Engineering by Technology - CRISPR, TALEN, ZFN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 66: Rest of World 7-Year Perspective for Genome Editing/Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, TALEN, ZFN and Other Technologies for the Years 2020 & 2027
  • Table 67: Rest of World Current & Future Analysis for Genome Editing/Genome Engineering by Application - Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 68: Rest of World 7-Year Perspective for Genome Editing/Genome Engineering by Application - Percentage Breakdown of Value Sales for Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering and Other Applications for the Years 2020 & 2027
IV. COMPETITION
  • Total Companies Profiled: 44
Note: Product cover images may vary from those shown
Adroll
adroll